NCT05424380View on ClinicalTrials.gov

A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS

PHASE1TerminatedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 20, 2022

Primary Completion Date

March 4, 2024

Study Completion Date

March 4, 2024

Conditions
Leukemia, Myeloid, Acute
Interventions
DRUG

GSK3745417

GSK3745417 will be administered

Trial Locations (10)

28033

GSK Investigational Site, Madrid

28040

GSK Investigational Site, Madrid

46026

GSK Investigational Site, Valencia

47014

GSK Investigational Site, Meldola FC

M5G 2M9

GSK Investigational Site, Toronto

01307

GSK Investigational Site, Dresden

04103

GSK Investigational Site, Leipzig

06132

GSK Investigational Site, Perugia

00168

GSK Investigational Site, Roma

3015 GD

GSK Investigational Site, Rotterdam

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT05424380 - A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS | Biotech Hunter | Biotech Hunter